A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)

Decker, Thomas; Overkamp, Friedrich; Rösel, Siegfried; Nusch, Arnd; Göhler, Thomas; Indorf, Martin; Sahlmann, Jörg; Trarbach, Tanja

doi:10.1186/s12885-017-3492-1

BMC Cancer

Article metrics
Last updated: Thu, 25 Apr 2024 21:39:50 Z

A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)

Access & Citations

2672

Article Accesses
18

Web of Science
19

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com